We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.66%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$89.3B
AUM Growth
+$8.23B
(+10%)
Cap. Flow
+$1.9B
Cap. Flow
% of AUM
2.12%
Top 10 Holdings %
Top 10 Hldgs %
24.87%
Holding
4,460
New
1,490
Increased
1,679
Reduced
1,235
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$60.1M |
| 2 |
TSMC
TSM
|
+$59.1M |
| 3 |
Tesla
TSLA
|
+$56M |
| 4 |
Apple
AAPL
|
+$55.2M |
| 5 |
Amazon
AMZN
|
+$47.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI ACWI ex US ETF
ACWX
|
+$102M |
| 2 |
Everest Group
EG
|
+$27.4M |
| 3 |
Chevron
CVX
|
+$25M |
| 4 |
Wells Fargo
WFC
|
+$24.9M |
| 5 |
Crane NXT
CXT
|
+$13.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.27% |
| 2 | Healthcare | 12.98% |
| 3 | Financials | 12.17% |
| 4 | Consumer Discretionary | 11.18% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ICVX
2751
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $391K | ﹤0.01% |
39,386
+4,746
| +14% | +$38K |
|
2752
Kodiak Sciences
KOD
$2.84B
| $390K | ﹤0.01% |
56,574
+1,890
| +3% | +$11.6K |
|
2753
Atlas Energy Solutions
AESI
$1.41B
| $390K | ﹤0.01% |
+22,442
| New | +$391K |
|
2754
Finance of America Companies
FOA
$198M
| $389K | ﹤0.01% |
20,362
+14,593
| +253% | +$245K |
|
2755
South Plains Financial
SPFI
$841M
| $387K | ﹤0.01% |
17,177
+1,238
| +8% | +$26.8K |
|
2756
Tucows
TCX
$175M
| $386K | ﹤0.01% |
13,929
+1,287
| +10% | +$33.2K |
|
2757
Intrepid Potash
IPI
$469M
| $386K | ﹤0.01% |
16,997
-683
| -4% | -$15.4K |
|
|
TELN
2758
DELISTED
TELENOR ASA
TELN
| $385K | ﹤0.01% |
+38,128
| New | +$385K |
|
|
AXIA
2759
AXIA Energia
AXIA
| $385K | ﹤0.01% |
+58,716
| New | +$336K |
|
2760
Wave Life Sciences
WVE
$1.2B
| $384K | ﹤0.01% |
+105,485
| New | +$426K |
|
|
MITSY
2761
DELISTED
MITSUI & CO LTD ADR (US)
MITSY
| $384K | ﹤0.01% |
+508
| New | +$384K |
|
2762
PMV Pharmaceuticals
PMVP
$63.5M
| $384K | ﹤0.01% |
61,314
+3,316
| +6% | +$17.4K |
|
2763
FirstService
FSV
$6.32B
| $383K | ﹤0.01% |
+2,485
| New | +$361K |
|
|
TSP
2764
DELISTED
TuSimple Holdings Inc. Class A Common Stock
TSP
| $382K | ﹤0.01% |
230,156
+16,074
| +8% | +$26K |
|
2765
Arbutus Biopharma
ABUS
$915M
| $381K | ﹤0.01% |
165,817
+6,690
| +4% | +$17.4K |
|
|
CIO
2766
DELISTED
City Office REIT
CIO
| $380K | ﹤0.01% |
68,218
-1,687
| -2% | -$9.2K |
|
2767
Clarus
CLAR
$143M
| $379K | ﹤0.01% |
41,480
+4,301
| +12% | +$38K |
|
|
AKZOY
2768
DELISTED
Akzo Nobel NV
AKZOY
| $379K | ﹤0.01% |
+13,869
| New | +$379K |
|
2769
ALX Oncology
ALXO
$290M
| $378K | ﹤0.01% |
50,350
+11,443
| +29% | +$74.9K |
|
2770
First Watch Restaurant Group
FWRG
$766M
| $377K | ﹤0.01% |
22,336
+287
| +1% | +$4.75K |
|
2771
ProFrac Holding
ACDC
$787M
| $377K | ﹤0.01% |
33,782
+8,351
| +33% | +$98.9K |
|
2772
iShares Russell Mid-Cap Growth ETF
IWP
$20.7B
| $376K | ﹤0.01% |
3,896
-741
| -16% | -$67.5K |
|
2773
SES AI
SES
$208M
| $376K | ﹤0.01% |
154,267
+140,392
| +1,012% | +$272K |
|
2774
GSK
GSK
$106B
| $376K | ﹤0.01% |
+10,545
| New | +$378K |
|
|
KALV
2775
DELISTED
KalVista Pharmaceuticals
KALV
| $376K | ﹤0.01% |
41,731
+2,909
| +7% | +$26.8K |
|
Similar funds
VAM
RhumbLine Advisers's Q2 2023 Portfolio in Review
As of Q2 2023, RhumbLine Advisers held 4,460 positions worth $89.3B, up 10% from $81B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
RhumbLine Advisers's Q2 2023 filing shows 1,490 new, 1,679 increased, 1,235 reduced and 38 closed positions. Its largest new stake was TSMC: 635,517 shares worth $64.1M. The largest sale was iShares MSCI ACWI ex US ETF, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
- RhumbLine Advisers's largest Q2 2023 buy was TSMC: 635,517 shares worth $64.1M.
- RhumbLine Advisers added most to Microsoft in Q2 2023, an estimated $60.1M increase.
- RhumbLine Advisers's biggest Q2 2023 reduction was iShares MSCI ACWI ex US ETF, cutting an estimated $102M.
- RhumbLine Advisers fully exited Everest Group in Q2 2023, selling an estimated $27.4M.
- RhumbLine Advisers's ten largest holdings make up 25% of its $89.3B portfolio in Q2 2023.
- RhumbLine Advisers opened 1,490 new positions and closed 38 in Q2 2023.
- RhumbLine Advisers's portfolio value rose 10% quarter-over-quarter to $89.3B.
Based on RhumbLine Advisers's 13F filing for Q2 2023, filed 8 Aug 2023.